Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

They also present Nuvalent, Inc. (NASDAQ:NUVL) with a cost-effective platform for boosting ... the company’s future due to its product Elevidys’ alleged involvement in a fatal acute liver ...

However, it said that DMD's severity means that Agamree is likely to offer a cost-effective use of NHS resources at the discounted price, according to NICE, which said that a new analysis provided ...

Dr. Peter Marks announced his resignation from the U.S. Food and Drug Administration (FDA) as Director of CEBR (Center for ...

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

Vykat extended-release tablets will be available in the U.S. beginning in April, and a list price of $5.92 per milligram, with the average baseline weight of participants in the C601 study being 61 ...